Fibrosis-related miRNAs as serum biomarkers for pancreatic ductal adenocarcinoma
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1821 views | HTML 2322 views | ?
Rei Suzuki1, Hiroyuki Asama1, Yuichi Waragai1, Tadayuki Takagi1, Takuto Hikichi2, Mitsuru Sugimoto1, Naoki Konno1, Ko Watanabe1, Jun Nakamura2, Hitomi Kikuchi2, Yuki Sato1, Shigeru Marubashi3, Atsushi Masamune4 and Hiromasa Ohira1
1Department of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima, Japan
2Department of Endoscopy, Fukushima Medical University Hospital, Fukushima, Japan
3Department of Hepato-Biliary-Pancreatic and Transplant Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan
4Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Japan
Rei Suzuki, email: [email protected]
Keywords: Pancreatic cancer; microRNA; fibrosis; digital PCR; chemotherapy
Received: May 24, 2017 Accepted: November 29, 2017 Published: December 17, 2017
We investigated whether serum microRNAs (miRNAs) could be diagnostic or prognostic markers in pancreatic ductal adenocarcinoma (PDAC). We first identified miRNAs showing altered expression in human pancreatic stellate cells (hPSCs) co-cultured with PDAC cells (Panc-1 and BxPC-3) as compared to hPSCs cultured alone. Among the miRNAs with altered expression, let-7d exhibited reduced expression in an in silico analysis of The Cancer Genome Atlas data. Inhibition of let-7d resulted in enhanced expression of fibrosis-related genes. We extracted serum miRNA from 45 PDAC patients and 42 healthy controls and quantified expression let-7d using digital PCR. Based on the level of let-7d expression, we were able to distinguish between PDAC patients and controls. Additionally, reduced let-7d expression correlated with poor overall survival. Thus, fibrosis-related miRNAs may be serum biomarkers for PDAC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.